ZA9811405B - A method for administration of levosimendan - Google Patents

A method for administration of levosimendan

Info

Publication number
ZA9811405B
ZA9811405B ZA9811405A ZA9811405A ZA9811405B ZA 9811405 B ZA9811405 B ZA 9811405B ZA 9811405 A ZA9811405 A ZA 9811405A ZA 9811405 A ZA9811405 A ZA 9811405A ZA 9811405 B ZA9811405 B ZA 9811405B
Authority
ZA
South Africa
Prior art keywords
levosimendan
patient
source
mucous membrane
administration
Prior art date
Application number
ZA9811405A
Other languages
English (en)
Inventor
Kauko Kurkela
Martti Marvola
Ilkka Larma
Raimo Virtanen
Marianne Karlsson
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corp filed Critical Orion Corp
Publication of ZA9811405B publication Critical patent/ZA9811405B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
ZA9811405A 1997-12-19 1998-12-11 A method for administration of levosimendan ZA9811405B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI974578A FI974578A (fi) 1997-12-19 1997-12-19 Menetelmä levosimendaanin antamiseksi

Publications (1)

Publication Number Publication Date
ZA9811405B true ZA9811405B (en) 1999-06-11

Family

ID=8550178

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9811405A ZA9811405B (en) 1997-12-19 1998-12-11 A method for administration of levosimendan

Country Status (26)

Country Link
US (1) US6399610B1 (xx)
EP (1) EP1052973B1 (xx)
JP (1) JP2001526205A (xx)
KR (1) KR100753689B1 (xx)
AT (1) ATE215358T1 (xx)
AU (1) AU738082B2 (xx)
BR (1) BR9813641A (xx)
CA (1) CA2313618C (xx)
CZ (1) CZ296693B6 (xx)
DE (1) DE69804678T2 (xx)
DK (1) DK1052973T3 (xx)
EA (1) EA002197B1 (xx)
EE (1) EE04330B1 (xx)
ES (1) ES2175827T3 (xx)
FI (1) FI974578A (xx)
HR (1) HRP20000400B1 (xx)
HU (1) HU226736B1 (xx)
IL (1) IL136415A (xx)
NO (1) NO320050B1 (xx)
NZ (1) NZ504806A (xx)
PL (1) PL191868B1 (xx)
PT (1) PT1052973E (xx)
RS (1) RS49889B (xx)
SK (1) SK284838B6 (xx)
WO (1) WO1999032081A1 (xx)
ZA (1) ZA9811405B (xx)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI980901A (fi) * 1998-04-23 1999-10-24 Orion Yhtymae Oyj Levosimendaania säädellysti vapauttavia oraalisia koostumuksia
FI20002755A0 (fi) 2000-12-15 2000-12-15 Orion Yhtymae Oyj Menetelmä erektiilin dysfunktion hoitamiseen
CN100428937C (zh) * 2003-10-30 2008-10-29 北京海合天科技开发有限公司 左西孟旦冷冻干燥组合物
FI20040674A0 (fi) * 2004-05-12 2004-05-12 Orion Corp Menetelmä tromboembolisten sairauksien estoon
EP1848270B1 (en) * 2005-02-17 2014-05-21 Abbott Laboratories Transmucosal administration of drug compositions for treating and preventing disorders in animals
CA2596768A1 (en) * 2005-02-18 2006-08-24 Orion Corporation A method for treating heart failure
WO2007096906A2 (en) * 2006-02-27 2007-08-30 Panacea Biotec Ltd. Novel buccoadhesive compositions and process of preparation thereof
CN101516426A (zh) * 2006-09-27 2009-08-26 尼克诺姆股份公司 定向用途
EP3941450A4 (en) * 2019-03-22 2022-12-21 Dbbh, Llc INTRANASAL ANTIHISTAMINES AND ASSOCIATED USES
WO2021001601A1 (en) * 2019-07-01 2021-01-07 Orion Corporation Methods for administering (r)-n-[4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)phenyl]acetamide
CA3161960A1 (en) 2019-12-16 2021-06-24 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (ph-hfpef)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2251615B (en) * 1991-01-03 1995-02-08 Orion Yhtymae Oy (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile
GB2266841A (en) 1992-05-06 1993-11-17 Orion Yhtymae Oy Compounds for use as anti-ischemic medicaments
US5688520A (en) * 1995-03-29 1997-11-18 Minnesota Mining And Manufacturing Company Transmucosal delivery of melatonin for prevention of migraine
GB9614098D0 (en) 1996-07-05 1996-09-04 Orion Yhtymae Oy Transdermal delivery of levosimendan

Also Published As

Publication number Publication date
AU738082B2 (en) 2001-09-06
KR100753689B1 (ko) 2007-08-30
DK1052973T3 (da) 2002-04-29
HRP20000400A2 (en) 2000-12-31
FI974578A (fi) 1999-06-20
HU226736B1 (en) 2009-08-28
JP2001526205A (ja) 2001-12-18
DE69804678T2 (de) 2002-11-21
IL136415A (en) 2005-03-20
EA002197B1 (ru) 2002-02-28
PL341202A1 (en) 2001-03-26
FI974578A0 (fi) 1997-12-19
HUP0100452A2 (hu) 2002-02-28
PT1052973E (pt) 2002-09-30
IL136415A0 (en) 2001-06-14
AU1565699A (en) 1999-07-12
EE200000368A (et) 2001-10-15
US6399610B1 (en) 2002-06-04
YU36900A (sh) 2003-02-28
EP1052973B1 (en) 2002-04-03
ES2175827T3 (es) 2002-11-16
NO20003059D0 (no) 2000-06-14
RS49889B (sr) 2008-08-07
ATE215358T1 (de) 2002-04-15
KR20010033368A (ko) 2001-04-25
CA2313618A1 (en) 1999-07-01
CZ296693B6 (cs) 2006-05-17
NZ504806A (en) 2001-09-28
SK9062000A3 (en) 2000-12-11
PL191868B1 (pl) 2006-07-31
NO20003059L (no) 2000-06-14
CA2313618C (en) 2008-02-05
DE69804678D1 (de) 2002-05-08
CZ20002155A3 (cs) 2000-11-15
EA200000686A1 (ru) 2000-12-25
EE04330B1 (et) 2004-08-16
WO1999032081A1 (en) 1999-07-01
BR9813641A (pt) 2000-10-17
SK284838B6 (sk) 2005-12-01
EP1052973A1 (en) 2000-11-22
HRP20000400B1 (en) 2009-06-30
HUP0100452A3 (en) 2002-03-28
NO320050B1 (no) 2005-10-17

Similar Documents

Publication Publication Date Title
AU1079701A (en) Oral transmucosal drug dosage using solid solution
PL320614A1 (en) Alendronate preparations for oral administration
WO1998035658A3 (de) Verwendung von 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzochinon
ZA9811405B (en) A method for administration of levosimendan
NZ507203A (en) Use of dexmedetomidine for ICU sedation
IL147876A0 (en) Use of agonists of gabab receptors and pharmaceutically acceptable derivatives thereof, in the therapy of maintaining nicotine abstinence-dependent patients
PL335561A1 (en) Application of levobupivacaine in face surgery
MY114716A (en) Prophylactic and/or therapeutic treatment of dyspeptic symptoms
MD1469G2 (ro) Metodă de tratament al şocului combustional
RU97115801A (ru) Способ лечения стенозирующих ларинготрахеитов у детей
RU97116821A (ru) Способ лечения респираторных заболеваний